Show simple item record

dc.contributor.authorJohnston, S
dc.contributor.authorSemiglazov, Vladimir F
dc.contributor.authorManikhas, George M
dc.contributor.authorSpaeth, Dominique
dc.contributor.authorRomieu, Gilles
dc.contributor.authorDodwell, David J
dc.contributor.authorWardley, Andrew M
dc.contributor.authorNeven, Patrick
dc.contributor.authorBessems, Annick
dc.contributor.authorPark, Youn C
dc.contributor.authorDe Porre, Peter M
dc.contributor.authorPerez Ruixo, Juan J
dc.contributor.authorHowes, Angela J
dc.date.accessioned2009-03-16T15:56:09Z
dc.date.available2009-03-16T15:56:09Z
dc.date.issued2008-07
dc.identifier.citationA phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. 2008, 110 (2):327-35 Breast Cancer Res. Treat.en
dc.identifier.issn1573-7217
dc.identifier.pmid17851757
dc.identifier.doi10.1007/s10549-007-9726-1
dc.identifier.urihttp://hdl.handle.net/10541/55793
dc.description.abstractBACKGROUND: This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy. PATIENTS AND METHODS: Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles. The primary endpoint was objective response rate. RESULTS: Of 120 patients treated with TL (n = 80) or L (n = 40), 113 were evaluable for response. Objective response rate was 30% (95% CI; 20-41%) for TL and 38% (95% CI; 23-55%) for L. There was no significant difference in response duration, time to disease progression or survival. Clinical benefit rates were 49% (TL) and 62% (L). Tipifarnib was generally well tolerated; a higher incidence of drug-related asymptomatic grade 3/4 neutropenia was observed for TL (18%) than for L (0%). Tipifarnib population pharmacokinetics were similar to previous studies, with no significant difference in trough letrozole concentrations between the TL and L groups. CONCLUSIONS: Adding tipifarnib to letrozole did not improve objective response rate in this population of patients with advanced breast cancer.
dc.language.isoenen
dc.subjectFarnesyltransferase Inhibitoren
dc.subjectTipifarniben
dc.subjectBreast Canceren
dc.subjectClinical Trialen
dc.subjectLetrozoleen
dc.titleA phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Breast Unit, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK. stephen.johnston@rmh.nhs.uken
dc.identifier.journalBreast Cancer Research and Treatmenten
html.description.abstractBACKGROUND: This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy. PATIENTS AND METHODS: Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles. The primary endpoint was objective response rate. RESULTS: Of 120 patients treated with TL (n = 80) or L (n = 40), 113 were evaluable for response. Objective response rate was 30% (95% CI; 20-41%) for TL and 38% (95% CI; 23-55%) for L. There was no significant difference in response duration, time to disease progression or survival. Clinical benefit rates were 49% (TL) and 62% (L). Tipifarnib was generally well tolerated; a higher incidence of drug-related asymptomatic grade 3/4 neutropenia was observed for TL (18%) than for L (0%). Tipifarnib population pharmacokinetics were similar to previous studies, with no significant difference in trough letrozole concentrations between the TL and L groups. CONCLUSIONS: Adding tipifarnib to letrozole did not improve objective response rate in this population of patients with advanced breast cancer.


This item appears in the following Collection(s)

Show simple item record